Treprostinil PatchPump - SteadyMed Therapeutics

Drug Profile

Treprostinil PatchPump - SteadyMed Therapeutics

Alternative Names: Trevyent

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SteadyMed Therapeutics
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Pulmonary arterial hypertension
  • Clinical Phase Unknown Pulmonary hypertension

Most Recent Events

  • 08 Dec 2017 SteadyMed expects both NDA submission and acceptance for Pulmonary arterial hypertension to occur before the end of 2018
  • 08 Dec 2017 SteadyMed receives final minutes from the US FDA for resubmission of New Drug Application for Pulmonary arterial hypertension
  • 14 Nov 2017 The United States Court of Appeals for the Federal Circuit upholds USPTO ruling on US Patent No. 8 497 393 against United Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top